 Apellis Pharmaceuticals said Friday the Food and Drug Administration will review its new eye-disease drug in February, and APLS stock surged. The post Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment appeared first on Investors Business Daily. 